Cost-effectiveness of dual influenza and pneumococcal vaccination in 50-year-olds

Vaccine

Volumn 28, Issue 48, 2010, Pages 7620-7625

  Smith, Kenneth J ^a   Lee, Bruce Y ^a   Nowalk, Mary Patricia ^a   Raymund, Mahlon ^a   Zimmerman, Richard K ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Cost effectiveness; Influenza vaccine; Pneumococcal polysaccharide vaccine; Secondary pneumococcal pneumonia

Indexed keywords

INFLUENZA VACCINE; PNEUMOCOCCUS VACCINE;

ADULT; ARTICLE; CASE REPORT; COMORBIDITY; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG UPTAKE; HEALTH CARE COST; HUMAN; INFLUENZA; INFLUENZA VACCINATION; PNEUMOCOCCAL INFECTION; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR;

CENTERS FOR DISEASE CONTROL AND PREVENTION (U.S.); COST-BENEFIT ANALYSIS; HUMANS; INFLUENZA VACCINES; INFLUENZA, HUMAN; MARKOV CHAINS; MIDDLE AGED; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; QUALITY-ADJUSTED LIFE YEARS; UNITED STATES; VACCINATION;

EID: 78249269475     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.09.053     Document Type: Article

References (30)

1. McCullers J.A. Insights into the interaction between influenza virus and pneumococcus. Clin Microbiol Rev 2006, 19(July (3)):571-582.
2. Pilishvili T., Lexau C., Farley M.M., Hadler J., Harrison L.H., Bennett N.M., et al. Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. J Infect Dis 2010, 201(January (1)):32-41.
3. Deaths, percent of total deaths, and death rates for the 15 leading causes of death in 5-year age groups, by race and sex. 2006. http://www%20cdc%20gov/nchs/datadvs/LCWK1_2006.pdf.
4. Center for Disease Control and Prevention. Self-reported pneumococcal vaccination coverage trends 1989-2008 among adults by age group, risk group, race/ethnicity, health-care worker status, and pregnancy status, United States, National Health Interview Survey (NHIS). 2008. Available from: URL: http://www.cdc.gov/flu/professionals/vaccination/pdf/NHIS89_08ppvvaxtrendtab.pdf.
5. Centers for Disease Control and Prevention. Self-reported influenza vaccination coverage trends 1989-2008 among adults by age group, risk group, race/ethnicity, health-care worker status, and pregnancy status, United States, National Health Interview Survey (NHIS). 2008. Available from: URL: http://www.cdc.gov/flu/professionals/vaccination/pdf/NHIS89_08fluvaxtrendtab.pdf.
6. Centers for Disease Control and Prevention. ACIP provisional recommendations for the use of influenza vaccines. 2010 March 2 [cited 2010 Mar 9]. Available from: URL: http://www.cdc.gov/vaccines/recs/provisional/downloads/flu-vac-mar-2010-508.pdf.
7. Maciosek M.V., Solberg L.I., Coffield A.B., Edwards N.M., Goodman M.J. Influenza vaccination health impact and cost effectiveness among adults aged 50 to 64 and 65 and older. Am J Prev Med 2006, (July):72-79.
8. Smith K.J., Zimmerman R.K., Lin C.J., Nowalk M.P., Ko F.S., McEllistrem M.C., et al. Alternative strategies for adult pneumococcal polysaccharide vaccination: a cost-effectiveness analysis. Vaccine 2008, (January):1420-1431.
9. Gold M., Siegel J., Russell L., Weinstein M. Cost-effectiveness in health and medicine 1996, Oxford University Press, New York.
10. Shapiro E.D., Berg A.T., Austrian R., Schroeder D., Parcells V., Margolis A., et al. The protective efficacy of polyvalent pneumococcal polysaccharide vaccine. N Engl J Med 1991, 325(21):1453-1460.
11. Braithwaite R.S., Meltzer D.O., King JTJr, Leslie D., Roberts M.S. What does the value of modern medicine say about the $50,000 per quality-adjusted life-year decision rule?. Med Care 2008, 46(4):349-356.
12. Laupacis A., Feeny D., Detsky A.S., Tugwell P.X. How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. CMAJ 1992, 146(February (4)):473-481.
13. Jackson L.A., Neuzil K.M. Pneumococcal polysaccharide vaccines. Vaccines 2008, Saunders Elsevier Inc., pp. 569-604. fifth ed.
14. Musher D.M., Manoff S.B., Liss C., McFetridge R.D., Marchese R.D., Bushnell B., et al. Safety and antibody response, including antibody persistence for 5 years, after primary vaccination or revaccination with pneumococcal polysaccharide vaccine in middle-aged and older adults. J Infect Dis 2010, 201(February (4)):516-524.
15. Jackson L.A., Benson P., Sneller V.P., Butler J.C., Thompson R.S., Chen R.T., et al. Safety of revaccination with pneumococcal polysaccharide vaccine. J Am Med Assoc 1999, 281:243-244.
16. O'Brien K.L., Hochman M., Goldblatt D. Combined schedules of pneumococcal conjugate and polysaccharide vaccines: is hyporesponsiveness an issue?. Lancet Infect Dis 2007, 7(9):597-606.
17. Davidson M., Bulkow L.R., Grabman J., Grabman J., Parkinson A.J., Chamblee C., et al. Immunogenicity of pneumococcal revaccination in patients with chronic disease. Arch Intern Med 1994, 154(19):2209-2214.
18. Manoff S.B., Liss C., Caulfield M.J., Marchese R.D., Silber J., Boslego J., et al. Revaccination with 23-valent pneumococcal polysaccharide vaccine induces elevated and persistent funtional antibody responses in adults aged >/65 years. J Infect Dis 2010, 201(February (4)):525-533.
19. Lexau C.A., Lynfield R., Danila R., Pilishvili T., Facklam R., Farley M.M., et al. Changing epidemiology of invasive pneumococcal disease among older adults in the era of pediatric pneumococcal conjugate vaccine. J Am Med Assoc 2005, 294(October (16)):2043-2051.
20. Sisk J.E., Whang W., Butler J.C., Sneller V.P., Whitney C.G. Cost-effectiveness of vaccination against invasive pneumococcal disease among people 50 through 64 years of age: role of comorbid conditions and race. Ann Int Med 2003, 138(12):960-968.
21. Gable C.B., Holzer S.S., Engelhart L., Friedman R.B., Smeltz F., Schroeder D., et al. Pneumococcal vaccine: efficacy and associated cost savings. J Am Med Assoc 1990, 264(22):2910-2915.
22. Plans-Rubio P. Pneumococcal polysaccharide vaccine: cost-effectiveness recommendations in adults. Expert Rev Pharmacoecon Outcomes Res 2005, 5(5):541.
23. Khazeni N., Hutton D.W., Garber A.M., Hupert N., Owens D.K. Effectiveness and cost-effectiveness of vaccination against pandemic influenza (H1N1) 2009. Ann Intern Med 2009, 151(12):829-839.
24. Lee B.Y., Brown S.T., Cooley P.C., Zimmerman R.K., Wheaton W.D., Zimmer S.M., et al. A computer simulation of employee vaccination to mitigate an influenza epidemic. Am J Prev Med 2010, 38(3):247-257.
25. Lee B.Y., Tai J.H., Smith K.J. The timing of influenza vaccination for older adults (65 years and older). Vaccine 2009, 27(50):7110-7115.
26. Jefferson T.O., Rivetti D., DiPietrantonj C., Rivetti A., Demicheli V. Vaccines for preventing influenza in healthy adults. Cochrane Database Syst Rev 2007, 2.
27. IOM report: patient safety - achieving a new standard for care. Acad Emerg Med 2005, 12(October (10)):1011-1012.
28. Gold M.R., Franks P., McCoy K.I., Fryback DG Toward consistency in cost-utility analyses: using national measures to create condition-specific values. Med Care 1998, 36(June (6)):778-792.
29. Sisk J.E., Whang W., Butler J.C., Sneller V.P., Whitney C.G. Cost-effectiveness of vaccination against invasive pneumococcal disease among people 50 through 64 years of age: role of comorbid conditions and race. Ann Intern Med 2003, 138(12):960-968.
30. Centers for disease control and prevention national immunization program vaccines for children. CDC price list. 2010 [cited 2010 May 27]. http://www%20cdc%20gov/nip/vfc/cdc_vac_price_list%20htm.